THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $530,012 | -20.5% | 61,415 | 0.0% | 0.00% | – |
Q2 2023 | $666,353 | 0.0% | 61,415 | 0.0% | 0.00% | – |
Q1 2023 | $666,353 | -8.7% | 61,415 | -5.6% | 0.00% | – |
Q4 2022 | $729,737 | -99.9% | 65,039 | -10.2% | 0.00% | – |
Q3 2022 | $734,320,000 | +11.9% | 72,418 | 0.0% | 0.00% | – |
Q2 2022 | $656,108,000 | -8.2% | 72,418 | -3.1% | 0.00% | – |
Q1 2022 | $714,735,000 | -12.8% | 74,763 | +0.8% | 0.00% | – |
Q4 2021 | $819,401,000 | +71.7% | 74,154 | +15.0% | 0.00% | – |
Q3 2021 | $477,301,000 | -48.6% | 64,500 | +0.9% | 0.00% | – |
Q2 2021 | $928,133,000 | -25.2% | 63,921 | +5.1% | 0.00% | -100.0% |
Q1 2021 | $1,240,806,000 | +14.9% | 60,794 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,080,310,000 | +68.3% | 60,794 | +40.0% | 0.00% | – |
Q3 2020 | $642,083,000 | -29.6% | 43,428 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $911,554,000 | +16.7% | 43,428 | +28.5% | 0.00% | 0.0% |
Q1 2020 | $781,211,000 | -10.6% | 33,804 | +0.1% | 0.00% | 0.0% |
Q4 2019 | $873,969,000 | +67.3% | 33,757 | +25.8% | 0.00% | – |
Q3 2019 | $522,551,000 | +143.7% | 26,825 | +104.3% | 0.00% | – |
Q2 2019 | $214,396,000 | -28.0% | 13,129 | 0.0% | 0.00% | – |
Q1 2019 | $297,635,000 | -42.9% | 13,129 | -35.6% | 0.00% | – |
Q4 2018 | $521,447,000 | -7.6% | 20,377 | +17.9% | 0.00% | – |
Q3 2018 | $564,440,000 | +172.9% | 17,277 | +89.5% | 0.00% | – |
Q2 2018 | $206,819,000 | -6.5% | 9,119 | 0.0% | 0.00% | – |
Q1 2018 | $221,136,000 | -53.6% | 9,119 | -46.6% | 0.00% | – |
Q4 2017 | $476,278,000 | -42.0% | 17,077 | -28.8% | 0.00% | -100.0% |
Q3 2017 | $821,692,000 | -1.0% | 23,998 | +15.2% | 0.00% | 0.0% |
Q2 2017 | $829,708,000 | +235.4% | 20,826 | +210.0% | 0.00% | – |
Q1 2017 | $247,394,000 | +115504.7% | 6,719 | 0.0% | 0.00% | – |
Q4 2016 | $214,000 | -50.9% | 6,719 | -44.1% | 0.00% | – |
Q3 2016 | $436,000 | +59.7% | 12,019 | 0.0% | 0.00% | – |
Q2 2016 | $273,000 | -96.7% | 12,019 | -97.5% | 0.00% | -100.0% |
Q1 2015 | $8,184,000 | +134.6% | 471,712 | +101.7% | 0.01% | +166.7% |
Q4 2014 | $3,488,000 | -34.4% | 233,812 | +1.3% | 0.00% | -40.0% |
Q3 2014 | $5,318,000 | -24.5% | 230,712 | +4.4% | 0.01% | -28.6% |
Q2 2014 | $7,043,000 | – | 220,912 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Madison Avenue Partners, LP | 7,012,226 | $78,677,176 | 13.94% |
Irenic Capital Management LP | 1,700,937 | $19,084,513 | 9.15% |
Weiss Asset Management LP | 7,457,060 | $83,668,213 | 3.41% |
Newtyn Management, LLC | 1,450,000 | $16,269,000 | 3.36% |
Palliser Capital (UK) Ltd | 97,100 | $1,089,462 | 2.65% |
Chescapmanager LLC | 850,988 | $9,548 | 2.24% |
Park West Asset Management LLC | 1,920,324 | $21,546,035 | 2.11% |
Baupost Group | 11,419,226 | $128,124 | 2.09% |
Saturn V Capital Management LP | 141,339 | $1,334,342 | 1.11% |
Oasis Management Co Ltd. | 296,960 | $3,331,891 | 0.66% |